PMID- 32497319
OWN - NLM
STAT- MEDLINE
DCOM- 20210810
LR  - 20210810
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Linking)
VI  - 45
IP  - 5
DP  - 2020 Oct
TI  - Comparison of double-dose vs standard-dose oseltamivir in the treatment of 
      influenza: A systematic review and meta-analysis.
PG  - 918-926
LID - 10.1111/jcpt.13203 [doi]
AB  - WHAT IS KNOWN AND OBJECTIVE: The effect of double-dose oseltamivir on mortality 
      in patients with influenza remains controversial. We systematically reviewed the 
      literature to investigate whether double-dose oseltamivir influences mortality in 
      patients with influenza. METHODS: PubMed, Excerpta Medica Database (Embase) and 
      Cochrane Central Register of Controlled Trials (CENTRAL) were searched for 
      randomized controlled trials (RCTs) and observational studies regarding the 
      effect of double-dose oseltamivir on mortality in patients with influenza. The 
      primary outcome was all-cause mortality. The Mantel-Haenszel method with random 
      effects model was used to calculate pooled odds ratios (ORs) and 95% confidence 
      intervals (CIs). RESULTS AND DISCUSSION: Ten studies (four RCTs and six 
      observational studies), involving 20 947 patients, were included. Pooled analysis 
      suggested that double-dose oseltamivir was not associated with decreased 
      mortality in patients with influenza, both in RCTs (OR, 1.29; 95% CI, 0.52-3.15; 
      P = .58) and observational studies (OR, 1.59; 95% CI, 0.79-3.19; P = .20; I(2) 
       = 51%). Double-dose oseltamivir did not show statistical benefit on the 
      virologic clearance rate (OR, 1.26; 95% CI, 0.85-1.88; P = .25; I(2)  = 0%) or 
      the incidence of adverse events (AEs) (OR, 1.52; 95% CI, 0.85-2.72; P = .15; I(2) 
       = 59%). WHAT IS NEW AND CONCLUSION: Current evidence indicates that double-dose 
      oseltamivir does not decrease mortality or have advantages on the outcome of 
      virologic clearance rate and incidence of AEs. However, the finding largely 
      relied on the data from observational studies, which may potentially have led to 
      selection bias. Therefore, high-quality and adequately powered RCTs are 
      warranted.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Li, Lei
AU  - Li L
AD  - Department of Pharmacy, Third Affiliated Hospital of Anhui Medical University, 
      Hefei, China.
FAU - Liu, Jing
AU  - Liu J
AD  - Department of Pharmacy, Third Affiliated Hospital of Anhui Medical University, 
      Hefei, China.
FAU - Qin, Kan
AU  - Qin K
AUID- ORCID: 0000-0001-8645-1459
AD  - Department of Pharmacy, Third Affiliated Hospital of Anhui Medical University, 
      Hefei, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200604
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Antiviral Agents)
RN  - 20O93L6F9H (Oseltamivir)
SB  - IM
MH  - Antiviral Agents/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Influenza, Human/*drug therapy/mortality
MH  - Oseltamivir/*administration & dosage
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
OTO - NOTNLM
OT  - double dose
OT  - influenza
OT  - mortality
OT  - oseltamivir
EDAT- 2020/06/05 06:00
MHDA- 2021/08/11 06:00
CRDT- 2020/06/05 06:00
PHST- 2019/10/30 00:00 [received]
PHST- 2020/04/28 00:00 [revised]
PHST- 2020/05/14 00:00 [accepted]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2021/08/11 06:00 [medline]
PHST- 2020/06/05 06:00 [entrez]
AID - 10.1111/jcpt.13203 [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2020 Oct;45(5):918-926. doi: 10.1111/jcpt.13203. Epub 2020 Jun 
      4.